Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL258692 | 0.87 | MGLL (0.36) | GLA | |
| SCHEMBL20624817 | 0.86 | — | — | |
| SCHEMBL16938480 | 0.83 | ALDH1A1 (0.33) | — | |
| SCHEMBL21232206 | 0.83 | — | — | |
| SCHEMBL17861182 | 0.83 | — | — | |
| SCHEMBL18916122 | 0.82 | TSHR (0.31) | — | |
| SCHEMBL13286374 | 0.82 | MGLL (0.32) | — | |
| SCHEMBL8402012 | 0.81 | MGLL (0.32) | — | |
| SCHEMBL15371562 | 0.80 | KMT2A (0.32) | — | |
| SCHEMBL12482068 | 0.79 | GLA (0.36) | GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11857638-B2 | Quinone-containing conjugates | PROMEGA CORPORATION (US) | 2024-01-02 | — | — | US | disclosed |
| US-11826485-B2 | Crosslinked gels comprising polyalkyleneimines, and their uses as medical devices | HYPERBRANCH MEDICAL TECHNOLOGY, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230295437-A1 | SILICON CONTAINING DETECTABLE COMPOUNDS | Singular Genomics Systems, Inc. | 2023-09-21 | — | — | US | disclosed |
| US-20230272002-A1 | PHOTOREDOX PROTEIN MODIFICATION | THE ROSALIND FRANKLIN INSTITUTE (GB) | 2023-08-31 | — | — | US | disclosed |
| US-11697736-B2 | Silicon containing detectable compounds | Singular Genomics Systems, Inc. (US) | 2023-07-11 | — | — | US | disclosed |
| WO-2023129518-A1 | TUBULYSINS AND PROTEIN-TUBULYSIN CONJUGATES | REGENERON PHARMACEUTICALS, INC. (US) | 2023-07-06 | — | — | WO | disclosed |
| US-20230160001-A1 | NUCLEOTIDE CLEAVABLE LINKERS WITH RIGID SPACERS AND USES THEREOF | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-05-25 | — | — | US | disclosed |
| US-11649452-B2 | High density sequencing and multiplexed priming | Singular Genomics Systems, Inc. (US) | 2023-05-16 | — | — | US | disclosed |
| US-20210386680-A1 | SELECTIVELY CLEAVABLE THERAPEUTIC NANOPARTICLES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2021-12-16 | — | — | US | disclosed |
| US-20210275718-A1 | Crosslinked Gels Comprising Polyalkyleneimines, And Their Uses As Medical Devices | HYPERBRANCH MEDICAL TECHNOLOGY, INC. | 2021-09-09 | — | — | US | disclosed |
| US-10688216-B2 | Crosslinked gels comprising polyalkyleneimines, and their uses as medical devices | HYPERBRANCH MEDICAL TECHNOLOGY, INC. (US) | 2020-06-23 | — | — | US | disclosed |
| US-20190001018-A1 | CROSSLINKED GELS COMPRISING POLYALKYLENEIMINES, AND THEIR USES AS MEDICAL DEVICES | HYPERBRANCH MEDICAL TECHNOLOGY, INC. | 2019-01-03 | — | — | US | disclosed |
| US-9878066-B2 | Crosslinked gels comprising polyalkyleneimines, and their uses as medical devices | HYPERBRANCH MEDICAL TECHNOLOGY, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170362266-A1 | Metabolic labeling and molecular enhancement of biological materials using bioorthogonal reactions | THE GENERAL HOSPITAL CORPORATION | 2017-12-21 | — | — | US | disclosed |
| US-20170199201-A2 | SURROGATES OF POST-TRANSLATIONALLY MODIFIED PROTEINS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-07-13 | — | — | US | disclosed |
| US-9417248-B2 | Surrogates of post-translationally modified proteins and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-08-16 | — | — | US | disclosed |
| US-9365721-B2 | Polycyclo dyes and use thereof | VISEN MEDICAL, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20150175998-A1 | Methods and Kits to Create Protein Substrate˜HECT-Ubiquitin Ligase Pairs | NORTHWESTERN UNIVERSITY | 2015-06-25 | — | — | US | disclosed |
| US-20140024056-A1 | SURROGATES OF POST-TRANSLATIONALLY MODIFIED PROTEINS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-01-23 | — | — | US | disclosed |
| US-7238339-B2 | Bifunctional chelating compounds containing hydroxamic acid residues | DRAXIS SPECIALTY PHARMACEUTICALS INC. (CA) | 2007-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10688216-B2 | Crosslinked gels comprising polyalkyleneimines, and their uses as medical devices | PLOD3, LIG3, PLOD2 | GLA 2117/4885 |
| US-11697736-B2 | Silicon containing detectable compounds | AS3MT, SCLY, NASP | GLA 425/4885 |
| US-20210275718-A1 | Crosslinked Gels Comprising Polyalkyleneimines, And Their Uses As Medical Devices | PLOD3, LIG3, PLOD2 | GLA 2117/4885 |
| US-20230295437-A1 | SILICON CONTAINING DETECTABLE COMPOUNDS | AS3MT, SCLY, NASP | GLA 425/4885 |
| US-20230272002-A1 | PHOTOREDOX PROTEIN MODIFICATION | PPOX, CACYBP, BRI3BP | GLA 3857/4885 |
| US-20210386680-A1 | SELECTIVELY CLEAVABLE THERAPEUTIC NANOPARTICLES | MMP10, MMP1, MMP3 | GLA 324/4885 |
| US-11826485-B2 | Crosslinked gels comprising polyalkyleneimines, and their uses as medical devices | PLOD3, LIG3, PLOD2 | GLA 2117/4885 |
| US-20140024056-A1 | SURROGATES OF POST-TRANSLATIONALLY MODIFIED PROTEINS AND USES THEREOF | CD59, SIGLEC9, CD209 | GLA 878/4885 |
| US-20170362266-A1 | Metabolic labeling and molecular enhancement of biological materials using bioorthogonal reactions | GALNT14, NEU4, CSGALNACT1 | GLA 27/4885 |
| US-11857638-B2 | Quinone-containing conjugates | NQO1, NQO2, SQOR | GLA 1955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.